The Medicines Co. spin-out Qpex launches with $33M in VC funding for antibiotics development
With New Enterprise Associates at the helm of the round, the company is setting out to develop antibiotics for drug-resistant bacterial infections.
Bivarus raises $4M Series B round to enhance data visualization and analytics for products
Bivarus plans to use some of the funding to add 10-15 new employees around the Research Triangle over the next year.
presented by
When Investment Rhymes with Canada
Canada has a proud history of achievement in the areas of science and technology, and the field of biomanufacturing and life sciences is no exception.
Morning Read: Hatteras Venture Partners raises $90M for fifth fund, BioMarin in $570M breast cancer drug deal
BioMarin Pharmaceutials is selling the global license for its PARP inhibitor talazoparibin to Medivation in a $570 million deal. Hatteras Venture Partners has raised $90 million as part of its first close for its fifth venture fund.
Ex-Genzyme CEO’s new company looks to rare diseases for insight into treating Parkinson’s
Scientists suspect there’s a connection between many common neurodegenerative diseases and malfunctioning lysosomes, or processing centers in human cells that break down proteins and eliminate debris. Now a new company called Lysosomal Therapeutics is tapping into the relationship between the two to discover and develop new treatments for rare diseases and common neurodegenerative diseases, starting […]
Applying neuromodulation to acute heart failure nets NC device startup a $13M series A
Neurostimulation devices that send mild electrical pulses to target nerves are arguably the fastest-growing segment of the medical devices sector. They’re primarily being commercialized in neurology and urology but are apparently showing promise in cardiology too. A startup called NeuroTronik spun out of medical device incubator Synecor last year says it’s raised a $13.1 million […]
Seed round will help radiation therapy startup prevent harmful effects of chemotherapy
One of the most common and most disruptive drawbacks of existing cancer chemotherapies is the toxic effect of bone marrow suppression that can result from a patient’s exposure to ionized radiation. The loss of red blood cells, white blood cells and platelets can cause anemia, fatigue and can increase the risk of infection, among other […]
Hatteras Ventures will invest up to $30M into ‘Discovery’
North Carolina venture capital firm Hatteras Venture Partners will use about 20 percent of an estimated $100 million to $150 million fourth fund to invest in seed-stage opportunities. The early stage portion of the next fund is dubbed Hatteras Discovery and will help companies through first-in-man and preclinical studies, Christy Shaffer, a venture partner and […]
N.C. pharma IT firm ArtusLabs bought by PerkinElmer; pair of deals total $220M
R&D software company ArtusLabs has been acquired by life science and health IT company PerkinElmer (NYSE:PKI) as one of a pair of deals intended to boost the Massachusetts company’s offerings for the pharmaceutical industry. Durham, North Carolina-based ArtusLabs’ software offers scientific data mining among other capabilities and is used by pharmaceutical industry researchers and others […]
Diabetes, cardiovascular drug developer PhaseBio adds $15M
The Philadelphia-area pharmaceutical company hopes for medical breakthroughs in Type 2 diabetes and hypertension. PhaseBio has embarked on Phase I and Phase II testing of its diabetes treatment, Glymera. Another treatment, Vasomera, focuses on hypertension. The $15 million was part of a total $25 million raised by the former Research Triangle Park/Duke University spinoff.